Form 4: KalVista CDO Yea Reports Routine Stock Transactions
Insider Transaction Report
KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, reported the acquisition of 1,774 shares from RSU settlement and the sale of 1,109 shares to cover tax obligations.
Summary
- Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, Inc. (KALV), reported transactions involving the company's common stock.
- On February 17, 2026, Yea acquired 1,774 shares of common stock through the settlement of Restricted Stock Units (RSUs).
- Each RSU represents a contingent right to receive one share of common stock upon settlement for no consideration.
- Following this acquisition, Yea's direct beneficial ownership was 225,282 shares.
- On February 18, 2026, Yea sold 1,109 shares of common stock at a price of $15 per share.
- This sale was a "sell to cover" transaction, specifically to satisfy tax withholding obligations related to the vesting and settlement of RSUs, and was not a discretionary transaction.
- After the sale, Yea's direct beneficial ownership stands at 224,173 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine transaction for tax purposes related to equity compensation rather than a discretionary sale or purchase reflecting a change in sentiment.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that 'sell to cover' transactions are a common practice for executives receiving equity compensation, particularly Restricted Stock Units (RSUs), to manage tax liabilities upon vesting. This type of transaction is generally not indicative of management's sentiment towards the company's future prospects, unlike discretionary sales.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not signaling a change in insider confidence.
- Employees: The vesting of RSUs is a positive for the reporting person as part of their compensation package.
Key Dates
| Date | Description |
|---|---|
| 02/17/2026 | Acquisition of 1,774 shares of Common Stock through RSU settlement. |
| 02/18/2026 | Disposition of 1,109 shares of Common Stock at $15 per share to cover tax withholding obligations. |
| 02/19/2026 | Date of filing of the Form 4. |
Keywords
KalVista Pharmaceuticals, KALV, Form 4, Insider Trading, Restricted Stock Units, RSU, Sell to Cover, Christopher Yea, Chief Development Officer, Stock Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.